Federal University of Sergipe Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial
2011
NCT01310738
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anxiety Disorders (Phase 2)

Leishmaniasis (Phase 4)

Leishmaniasis, Visceral (Phase 4)

Tooth, Impacted (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 6